SecurityPFN / PIMCO Income Strategy Fund II
Institutional Owners10 (9 N-Q Owners)
Institutional Shares1,900 (ex. N-Q)

Institutional Stock Ownership and Shareholders

PIMCO Income Strategy Fund II (NYSE:PFN) has 10 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,900 shares. Largest shareholders include Bank Of America Corp /de/.
PIMCO Income Strategy Fund II (NYSE:PFN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-03-29 N-Q Powershares Exchange-traded Fund Trust Ii (see advisory)
2018-03-29 N-Q Sunamerica Specialty Series (see advisory)
2017-12-29 N-Q Pimco Income Strategy Fund Ii (see advisory)
2018-02-13 SC 13D/A BANK OF AMERICA CORP /DE/ 1,900
2018-04-20 N-Q Graniteshares Etf Trust (see advisory)
2017-11-28 N-Q Cohen & Steers Closed-end Opportunity Fund, Inc. (see advisory)
2017-11-28 N-Q Cohen & Steers Global Income Builder, Inc (see advisory)
2018-02-20 N-Q Psg Capital Management Trust (see advisory)
2018-02-28 N-Q Guggenheim Funds Trust (see advisory)
2018-03-28 N-Q Old Westbury Funds Inc (see advisory)

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.


  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( PFN / PIMCO Income Strategy Fund II ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

High-Income, Sustainable-Capital Portfolio: Reviewing A Rough Quarter

2018-04-02 seekingalpha
Income remains strong, however. The quarter's distribution yield was 2.8% for an annualized yield of 11.2%. (3-0)

Pimco Income Strategy Fund II: Fairly Priced, Mixed Outlook, But Still A Buy

2018-03-19 seekingalpha
PFN has seen year-over-year (YOY) gains to both its share price and net asset value (NAV). (41-0)

Nuveen Credit Strategies: How To Avoid The Big Dividend Cut

2018-03-05 seekingalpha
The closed-end fund Nuveen Credit Strategies (JQC) just cut its dividend 13.7% from 0.0475 to 0.0410 per month. (40-0)

PTY: Same Concerns Exist

2018-02-05 seekingalpha
The purpose of this article is to articulate why I believe PIMCO Corporate & Income Opportunity Fund (NYSE:PTY) is not an attractive investment option at its current market price. While PTY's NAV has been steadily increasing, the fund's share price represents a premium to NAV that remains stubbornly high, indicating it may be overpriced. Other Pimco funds offer a similar investment strategy, but currently offer a cheaper valuation. (41-0)

PDI Shines In PIMCO's November CEF Report

2017-12-17 seekingalpha
The standout fund is PDI which has maintained the strong distribution coverage ratio it showed last month and moves to its highest level of net investment income in six months. (2-1)